TipRanks
VistaGen Therapeutics (VTGN)
NASDAQ:VTGN
US Market
VTGN
VistaGen Therapeutics
RESEARCH TOOLSreports
Want to see VTGN full AI Analyst Report?

VistaGen Therapeutics (VTGN) Income Statement

1,156 Followers

VistaGen Therapeutics Income Statement

Last quarter (Q1 2027), VistaGen Therapeutics's total revenue was $1.48M, an increase of 504.92% from the same quarter last year. In Q1, VistaGen Therapeutics's net income was $-13.03M. See VistaGen Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Mar 26Mar 25Mar 24Mar 23Mar 22
Total Revenue
$ 1.27M$ 486.00K$ 1.06M$ -227.00K$ 1.11M
Gross Profit
$ 1.27M$ 486.00K$ 1.06M$ -227.00K$ 1.11M
Operating Expenses
$ 73.39M$ 56.46M$ 34.09M$ 59.04M$ 48.89M
Depreciation and Amortization
$ 733.00K$ 635.00K$ 568.00K$ 532.00K$ 711.10K
EBITDA
$ -71.39M$ -50.78M$ -28.79M$ -58.74M$ -47.05M
Operating Income
$ -72.13M$ -55.97M$ -33.02M$ -59.27M$ -47.78M
Other Income/Expenses
$ 2.45M$ 4.56M$ 3.66M$ 26.00K$ 19.90K
Pretax Income
$ -69.68M$ -51.41M$ -29.36M$ -59.24M$ -47.76M
Net Income
$ -69.69M$ -51.42M$ -29.36M$ -59.25M$ -47.76M
Per Share Metrics
Basic EPS
$ -1.83$ -1.67$ -1.52$ -8.51$ -7.38
Diluted EPS
$ -1.83$ -1.67$ -1.52$ -8.51$ -7.38
Weighted Average Shares Outstanding
 38.07M 30.88M 19.35M 6.96M 6.60M
Weighted Average Shares Outstanding (Diluted)
 38.07M 30.88M 19.35M 6.96M 6.60M
Currency in USD

VistaGen Therapeutics Earnings and Revenue History